Media stories about OvaScience (NASDAQ:OVAS) have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. OvaScience earned a media sentiment score of 0.04 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 44.5246519904865 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

A number of analysts have issued reports on OVAS shares. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of OvaScience in a research note on Monday, November 6th. Zacks Investment Research upgraded shares of OvaScience from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research note on Wednesday, October 4th.

Shares of OvaScience (NASDAQ:OVAS) traded up $0.03 during trading on Friday, hitting $1.38. The stock had a trading volume of 1,290,200 shares, compared to its average volume of 573,152. OvaScience has a 1-year low of $1.25 and a 1-year high of $3.25.

TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact OvaScience (OVAS) Share Price” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-ovascience-ovas-share-price/1765936.html.

About OvaScience

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Insider Buying and Selling by Quarter for OvaScience (NASDAQ:OVAS)

Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.